Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Varicella

Varicella

Part of Herpesviridae Infections

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Varicella

31 trials tracked for Varicella: 23 in phase 3 or 4 and 10 with published results. The most-cited published study has 96 citations.

31Trials tracked
23Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 3 23 Phase 2 5 Other / NA 3
  1. Phase 3 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed · 96 cited
  2. Phase 3 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed · 30 cited
  3. Phase 3 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed · 19 cited
  4. Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV Completed · 19 cited
  5. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
  6. Phase 3 ProQuad® Intramuscular vs Subcutaneous Completed · 10 cited
Show 25 more trials
  1. Phase 3 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed · 10 cited
  2. Phase 3 Safety Study of ProQuad® rHA in Infants (V221-037) Completed · 9 cited
  3. Phase 3 Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) Completed · 3 cited
  4. Phase 3 Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) Completed · 2 cited
  5. Phase 3 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed
  6. Phase 3 Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients Completed
  7. Phase 3 Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) Completed
  8. Phase 3 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed
  9. Phase 3 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed
  10. Phase 3 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed
  11. Phase 3 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed
  12. Phase 3 Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) Completed
  13. Phase 3 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed
  14. Phase 3 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
  15. Phase 3 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed
  16. Phase 3 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed
  17. Phase 3 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed
  18. Phase 2 ProQuad Dose Selection Study (V221-011)(COMPLETED) Completed
  19. Phase 2 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Completed
  20. Phase 2 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed
  21. Phase 2 Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). Completed
  22. Phase 2 Study of Two Formulations of GSK Biologicals' Varicella Vaccine Completed
  23. N/A Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox) Completed
  24. N/A Re-examination Study For Varivax (V210-059 AM2) Completed
  25. N/A A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED) Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Varicella: what the trials found

Multiple phase 3 trials demonstrate that varicella vaccines (e.g., Priorix-tetra™, ProQuad®, VARIVAX™) are highly immunogenic, with seroconversion rates exceeding 95% and geometric mean titers (GMTs) significantly increasing post-vaccination 125691013141819202122. For instance, in trial NCT00226499, the number of confirmed varicella cases was significantly reduced (p<0.0001) in vaccinated groups 1. Similarly, NCT00566527 showed that over 98% of participants met antibody response criteria after a second dose of ProQuad® 2.

Vaccination also reduces disease severity. In NCT00226499, the number of moderate or severe varicella cases was significantly lower in the vaccine group (2 vs 37 vs 117, p=0.0001) 1. Immunogenicity is consistent across different vaccine formulations and processes, as seen with VARIVAX™ new seed process (97.2% seroconversion, p<0.001) 13 and MMRV vaccines 1419202122.

Safety profiles are generally acceptable, with solicited local and systemic reactions reported but mostly mild. For example, in NCT00969436, grade 3 solicited local symptoms were rare (0-1 subjects) 4, and fever rates were comparable between groups (e.g., 9.5-10.5% in NCT02062502) 13. In NCT00560755, 41.77% of participants experienced a vaccine-related adverse event after the second dose of ProQuad® 8.

For the clinician treating this condition

  • Varicella vaccines (e.g., Priorix-tetra™, ProQuad®, VARIVAX™) are highly effective in inducing seroconversion and reducing varicella cases, including moderate-to-severe disease.
  • Immunogenicity is robust across different vaccine formulations and manufacturing processes, with seroconversion rates consistently above 95%.
  • Safety is acceptable, with most adverse events being mild and self-limited; fever and injection-site reactions are the most common.

AI synthesis of 15 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GSK investigational MMRV vaccine shows comparable immunogenicity to licensed MMRV in healthy children
Pediatrics RCT
GSK investigational MMRV vaccine shows comparable immunogenicity to licensed MMRV in healthy children GSK MMRV vaccine shows comparable safety and immune response to licensed MMRV in young children
This randomized, multi-country phase II trial in 801 healthy children aged 4-6 years found that one dose of a GSK investigational MMRV vacci…
A Phase II trial in healthy children found the investigational GSK MMRV vaccine produced immune responses and safety similar to the licensed…
May 27, 2026
Random forest model predicts pediatric varicella encephalitis with excellent performance in a retrospective analysis
Infectious Disease Cohort
Random forest model predicts pediatric varicella encephalitis with excellent performance in a retrospective analysis A Simple Checklist Could Catch the Most Dangerous Chickenpox Complication Early
This retrospective analysis evaluated a random forest model for predicting pediatric varicella encephalitis in 201 children.
A new AI tool predicts dangerous chickenpox brain complications in kids with 95% accuracy using just six simple symptoms like rash duration …
Frontiers Apr 18, 2026
Field report describes expanded laboratory testing for varicella in Minnesota
Infectious Disease
Field report describes expanded laboratory testing for varicella in Minnesota What happens when health departments test more people for chickenpox?
A descriptive field report from the Minnesota Department of Health outlines expanded laboratory testing for varicella.
Minnesota health officials are testing more people for chickenpox to better track how much of the virus is circulating in their community.
CDC Apr 4, 2026
Varicella outbreak reported among recent arrivals from Central and South America in NYC shelters
Infectious Disease
Varicella outbreak reported among recent arrivals from Central and South America in NYC shelters Chickenpox outbreak hits New York City shelters for recent arrivals
An outbreak report describes varicella cases among people recently arriving from Central or South America and staying in New York City shelt…
A chickenpox outbreak is spreading among recent arrivals from Central and South America living in New York City shelters and residential fac…
CDC Apr 4, 2026

Research across Herpesviridae Infections

Related studies from across the Herpesviridae Infections family.

Case report describes congenital varicella syndrome in Illinois
Infectious Disease
Case report describes congenital varicella syndrome in Illinois Doctors describe a single case of congenital varicella syndrome in Illinois
A single case report describes congenital varicella syndrome in Illinois.
Illinois doctors documented a single case of congenital varicella syndrome, a rare condition affecting babies born to parents who contracted…
CDC Apr 6, 2026

Questions about Varicella

Does the field report describe new Varicella testing in Minnesota?

Yes, a field report confirms that the Minnesota Department of Health has expanded laboratory testing for varicella.

Full answer →
How well did the random forest model perform for Varicella?

A random forest model predicted pediatric varicella encephalitis with an area under the curve of 0.950, showing excellent performance in a study of 201 children.

Full answer →